Generic Semaglutide: When Patents Expire and What's Approved (2026)

As of September 24, 2026, there’s no generic Ozempic or Wegovy on the US market. The FDA’s Orange Book lists the patent on the semaglutide substance until December 5, 2031^[1], and Novo Nordisk puts US compound patent expiry at 2032^[11]. One generic, from Apotex, has a tentative approval that doesn’t allow it to be sold^[3,4]. Outside the US, the picture has changed fast: generic semaglutide is already approved in Canada, India and Brazil, where the main protection ended in early 2026^{[11,15,19,20,23]}.

This page is about dates: patents, data protection and approvals. What each brand name means, and the difference between generic, hybrid and biosimilar, is in GLP-1 generic and brand names. I don’t cover doses or switching here; those are questions for your prescriber.

Is there a generic Ozempic in the US?

Not yet. Three things decide when one arrives:

• Patents in the Orange Book. The FDA’s patent register lists the semaglutide substance patent for Ozempic until December 5, 2031. The latest patent it lists for Ozempic, a method-of-use patent, runs to June 21, 2033^[1]. Novo Nordisk’s 2025 annual report gives 2032 for the US compound patent, including actual and estimated extensions^[11].
• Patent challenges. Several companies have filed abbreviated new drug applications (ANDAs) for generic Ozempic, Wegovy and Rybelsus that challenge those patents, and Novo Nordisk has sued them. Novo reports settling with some of them on terms that are confidential (Form 20-F)^[12]. Its first-half 2026 report adds a patent suit against Cipla over an Ozempic ANDA^[13]. Because the settlement terms aren’t public, no public record gives a launch date.
• Tentative approval. The FDA granted Apotex’s semaglutide injection a tentative approval on April 7, 2026^[3]. According to the Drugs@FDA glossary, that means the product meets the requirements but patents or exclusivities still block it, and it can’t be marketed yet^[4].

On July 28, 2026, the FDA also published 17 revised draft guidances for developing generic peptides, including Ozempic, Wegovy, Mounjaro and Zepbound. They cover copies made by recombinant, synthetic or semi-synthetic processes. They’re drafts, and they describe how to develop a generic, not when one can launch^[5].

Generic semaglutide by country: patents and approvals

Sources: Novo Nordisk’s patent table (page 25), the Orange Book^[1,11], and the regulators and press cited in each section below.

Novo Nordisk’s dates are for the active-ingredient patent and include extensions. The company notes it may hold other patents on manufacturing, formulations or uses, and that data protection may also apply^[11]. A patent date isn’t a launch date.

What “generic” means for a peptide drug

Semaglutide is a peptide, a chain of amino acids. Novo Nordisk makes it with living cells: the US label says the peptide backbone is produced by yeast fermentation (Ozempic prescribing information)^[6]. Many of the copies approved in 2026, such as Brazil’s and Sandoz’s in Canada, are made by chemical synthesis instead^[18,23]. Regulators handle that difference in different ways:Dotted underline: a drug-label fact; hover over it to see the date it was checked.

• US. Copies go through the generic route, the ANDA, and the FDA’s 2026 draft guidances cover synthetic copies of peptides originally made with recombinant DNA^[3,5].
• Canada. Sandoz describes its copy as a complex synthetic product that is pharmaceutically equivalent to the brand-name biologic. Health Canada authorizes these as generics^[15,18].
• European Union. Copies are filed under Article 10 of Directive 2001/83/EC, which the EMA calls a “generic, hybrid or similar biological application”^[30]. The EMA’s list classes the three pending semaglutide applications as “Chemicals”^[31]. There’s a precedent: in July 2026 the EU authorized synthetic liraglutide as a hybrid of Victoza, which is made with living cells (Liraglutide STADA)^[33]. A synthetic peptide guideline in force since June 1, 2026 covers synthetic peptides whose reference medicine is biological^[32].
• Brazil. Anvisa says a biologic can’t be registered as a generic, and calls these copies “synthetic analogs of biological peptides”^[22]. Ozivy and the five July copies were registered by comparison with Ozempic^[23,24]; the generic and the “similar” approved in August use Ozivy as their reference instead^[25].
• Chile. The regulator, the ISP, told La Tercera that its seven applications are of chemical origin, unlike Ozempic, so approval “can’t be automatic”^[42].

So “generic” doesn’t mean exactly the same thing everywhere. What these routes share is a regulator’s quality review before the product can be sold. Definitions are in the glossary: generic drug and biosimilar.

Patents, extensions and data protection: why the dates differ

A generic can be blocked by three separate things, each with its own end date:

1. The active-ingredient patent. It usually lasts 20 years from filing, the minimum set by the WTO’s TRIPS Agreement on intellectual property^[45]. In Brazil, the Superior Court of Justice refused in January 2026 to extend the semaglutide patent, Agência Brasil reported, and it expired on March 20^[26].
2. Extensions. The US, the EU and Japan can extend a drug patent to make up for time lost in regulatory review. Novo Nordisk’s dates of 2031 or 2032 for the US, Europe and Japan already include these extensions^[11].
3. Data protection. For a period, a generic maker can’t rely on the brand’s clinical trial data. In the EU, according to the EMA, a generic can only be marketed once the brand’s protection has expired, usually 10 or 11 years after its first authorization^[29].

China shows how these layers stack. The patent expired on March 20, 2026, but Novo Nordisk says Ozempic has regulatory data protection until April 2027 under the China-Switzerland free trade agreement, Bloomberg reported. At least one Chinese company has said the review of its application is suspended for that reason^[28].

Generic semaglutide outside the US

Canada: the first G7 country with generic semaglutide

According to Canadian patent office documents reported by CNBC, Novo Nordisk last paid the annual maintenance fee on its Canadian semaglutide patent in 2018, and the patent lapsed for non-payment. Even so, semaglutide stayed protected in Canada until January 2026^[19].

Health Canada’s approvals:

• April 28, 2026. The first generic semaglutide, from Dr. Reddy’s, referencing Ozempic for type 2 diabetes. It was the first in the G7^[15].
• May 1, 2026. The second, from Apotex, also referencing Ozempic^[16].
• June 29, 2026. Sevmia, from Apotex: the first generic of Wegovy, for chronic weight management. Six more applications were under review at the time^[17].
• September 18, 2026. Sandoz announced approval of its generic Ozempic^[18].

In its first-half 2026 report, Novo Nordisk says the loss of exclusivity in Canada has lowered the prices it realizes there^[13].

India: launches the day after the patent expired

The patent expired on Friday, March 20, 2026. The next day, Dr. Reddy’s launched Obeda for type 2 diabetes; the company says it was the first Indian firm to receive approval from the national regulator (DCGI) for generic semaglutide^[20]. At least five Indian drugmakers launched versions that weekend, and more than 50 brands were expected in the following months, CNBC reported. The launch prices it reported were about 50% below the original for Sun Pharma and Dr. Reddy’s, and nearly 80% below for smaller makers^[21]. Those are Indian prices from March 2026, not a guide for other countries.

Brazil: a synthetic copy first, then its generics

On March 20, 2026, the day the patent expired, Anvisa had eight applications under review: seven synthetic and one biological^[22]. It registered Ozivy, from EMS, on May 26, 2026^[23], and five more on July 29, all for type 2 diabetes^[24]. On August 17 it registered an unbranded generic (EMS) and a “similar” called Semaclique (Germed), which Anvisa rates as interchangeable with Ozivy, their reference product^[25].

China: patent expired, no approved copies found

The core patent expired on March 20, 2026. Several Chinese drugmakers, including Hangzhou Jiuyuan, Livzon and Qilu, had filed for approval of their semaglutide in 2024, according to the South China Morning Post^[27]. With the data protection dispute described above, I found no copy approved by China’s regulator (NMPA) as of September 24, 2026.

European Union: 2031

Novo Nordisk puts expiry in Europe at 2031, based on Germany, and notes that patent status varies by country^[11]. The EMA’s September 2026 list includes three semaglutide copies under evaluation: two for type 2 diabetes and one for weight management. Their reviews started on May 21 and June 18, 2026^[31]. Ozempic was authorized in the EU on February 8, 2018^[34], so under the usual 10- or 11-year rule its EU data protection would end in 2028 or 2029, before the patent date Novo Nordisk gives.

Latin America

• Mexico. The only semaglutide products on the list of registrations COFEPRIS published in May 2024 are Ozempic, Rybelsus and Wegovy^[35]. In March 2026, a patent lawyer quoted by Excélsior said generic applications had been filed but none approved^[36]. Mexican press disagrees on the patent: Expansión reported it expired in March 2026^[37], while Milenio quoted a pharmaceutical chemist who put the end of protection at December 2027^[38]. I couldn’t confirm either with Mexico’s patent office (IMPI).
• Argentina. The national regulator, ANMAT, approved Dutide, Laboratorio Elea’s semaglutide injection, on March 13, 2025, Infobae reported^[39]. Its package insert cites Ministry of Health certificate 60.181^[40]. Obetide, Elea’s version for weight management, followed in November 2025, La Nación reported^[41].
• Chile and Colombia. Chile’s ISP has seven applications, including Laboratorio Chile’s Selfix, still pending in July 2026 according to La Tercera^[42]; on September 23, 2026, none appeared in the ISP registry^[43]. In Colombia, every current semaglutide registration in the INVIMA database belongs to Novo Nordisk^[44].

Compounded semaglutide isn’t a generic

This is the most common mix-up in the US. The FDA draws the line: a generic “is approved by FDA” under section 505(j) of the law, “while a compounded drug is not approved by FDA.” The agency doesn’t review compounded drugs for safety, effectiveness or quality before they’re sold^[7].

Compounders had extra leeway while semaglutide was on the FDA’s shortage list. The FDA declared that shortage resolved on February 21, 2025, and gave pharmacies until April 22, 2025, and outsourcing facilities until May 22, 2025, to stop making essentially copies of the approved product^[8]. As of May 31, 2026, the FDA had received 990 adverse event reports involving compounded semaglutide^[9].

A vial or pen labeled only “semaglutide” isn’t an FDA-approved generic: none is on the US market yet. More in the glossary entries for compounded drug and falsified medicine.

What about generic tirzepatide?

There isn’t one in any country on this page. In its 10-K, Eli Lilly estimates that the compound patent for Mounjaro and Zepbound expires in 2036 in the US, 2037 in major European countries and 2040 in Japan. The same table puts US data protection at 2027^[14]. The Orange Book lists the tirzepatide substance patent until May 13, 2036^[2].

What generics could mean for price

Generics usually bring prices down, and more so as more makers compete. An FDA analysis of drugs that got their first generic between 2015 and 2017 measured it with average manufacturer prices (median values)^[10]:

Health Canada notes in its announcements that many generics in Canada cost 45% to 90% less than the brand^[15,17]. These are general figures, not a forecast for semaglutide. It’s an injectable peptide that’s more complex to make than most drugs, CNBC reported. Chemist Knud Jensen, president of the European Peptide Society, told the outlet that quality control for these large molecules is harder than for small ones^[21]. And US patents still have years to run^[1]. For current brand list prices, see the monthly cost calculator.

A generic existing also doesn’t mean your insurer or health system will cover it. If a generic interests you, it’s worth raising with your prescriber; the doctor visit checklist can help you prepare.

Frequently asked questions

When does the Ozempic patent expire in the US?

The Orange Book lists the semaglutide substance patent until December 5, 2031, and the latest patent listed for Ozempic, a method-of-use patent, until June 21, 2033^[1]. Novo Nordisk gives 2032 for the compound patent, including extensions^[11]. The terms of Novo’s settlements with generic makers are confidential^[12], so none of these dates is a launch date.

Is there a generic Wegovy?

Not in the US. Canada approved the first generic of Wegovy, Apotex’s Sevmia, on June 29, 2026, for chronic weight management^[17]. In the EU, one of the three semaglutide applications under EMA review is for weight management^[31].

Which countries already have generic semaglutide?

As of September 24, 2026: Canada, with at least four approvals since April^{[15,16,17,18]}; India, where generics went on sale in March^[20]; and Brazil, since May^[23]. Argentina has had Dutide, a semaglutide from Laboratorio Elea, since 2025^[39]. In China the patent expired^[27], but I found no approved copy.

Why does Canada have generic semaglutide before the US?

Novo Nordisk’s Canadian semaglutide patent lapsed after an unpaid maintenance fee, according to patent office documents reported by CNBC, and protection ended in January 2026^[19]. In the US, the Orange Book still lists the substance patent until December 5, 2031^[1].

When does the Mounjaro and Zepbound patent expire?

Eli Lilly estimates the tirzepatide compound patent runs to 2036 in the US, 2037 in major European countries and 2040 in Japan^[14]. The Orange Book lists the substance patent until May 13, 2036^[2]. No generic tirzepatide exists in any country on this page.